Chr. Hansen’s Probiotic Strain DDS-1® Authorized by Health Canada for Stress Relief in IBS

Chr. Hansen’s Probiotic Strain DDS-1® Authorized by Health Canada for Stress Relief in IBS

(IN BRIEF) Health Canada has granted authorization for the probiotic strain Lactobacillus acidophilus DDS-1® to make health claims related to the gut-brain axis. The strain is now approved to help alleviate perceived stress, improve irritable bowel syndrome (IBS)-related quality of life, alleviate perceived stress in conjunction with improving abdominal pain, and normalize stool consistency in adolescents and adults with IBS. This recognition strengthens the scientific foundation of the probiotic product and provides credibility in the emerging field of the gut-brain axis. It is expected to increase interest in clinically documented probiotics, both in Canada and other global markets. DDS-1® is a registered trademark of Chr. Hansen A/S.

(PRESS RELEASE) HØRSHOLM, 8-Nov-2023 — /EuropaWire/ — Recent research in the emerging field of the gut-brain axis has highlighted the intricate relationship between the brain, gut, and microbiome, shedding light on its profound impact on both physical and mental well-being. For individuals with irritable bowel syndrome (IBS), the emotional toll is well-documented, as they often experience feelings of sadness, embarrassment, and self-consciousness, significantly affecting their quality of life and social participation¹.

Chr Hansen Holding A/S (CPH: CHR), a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries, announces that its probiotic strain Lactobacillus acidophilus DDS-1® has already received Health Canada’s authorization for improving abdominal pain severity and symptomology in adolescents and adults with IBS. Building on this achievement, the existing Natural Health Product (NPH) license for DDS-1® in Canada has been expanded to encompass several gut-brain axis claims:

1. Alleviates perceived stress in adolescents and adults with irritable bowel syndrome.
2. Enhances irritable bowel syndrome-related quality of life in adolescents and adults.
3. Alleviates perceived stress while improving abdominal pain in adolescents and adults with irritable bowel syndrome.
4. Normalizes stool consistency in adolescents and adults with irritable bowel syndrome.

“We are excited that one of our probiotic strains has received official Canadian health claims relating to the gut-brain axis, putting a quality stamp on the science behind our product and adding credibility to our offering in this emerging field,” says Niklas Larsson, PhD, Head of Scientific Affairs, Chr. Hansen Human Health.

“It will assist consumers in making informed health choices when selecting probiotics and reinforce their confidence that the products are effective, safe and of high quality. Officially registered health claims will drive increased interest in our clinically documented probiotics and their potential benefit in general, both in Canada and other markets,” concludes Linda Neckmar, SVP, Chr. Hansen Human Health.

DDS-1^® is a trademark of Chr. Hansen A/S.

This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers on final consumer goods. Please check your local regulations for acceptable claims in the market.

¹International Foundation for Functional Gastrointestinal Disorders (IFFGD). IBS patients: Their illness experience and unmet needs. An online study. 2009.

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for almost 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.

Media contact:

Helle Rexen
Media Relations Officer
Corporate Communications
Hoersholm , Denmark
+45 20 74 28 40

Kathrine Westermann
Head of Media Relations
Corporate Communications
Hoersholm , Denmark
+45 23 81 55 95

SOURCE: Chr. Hansen Holding A/S